Pasithea Therapeutics Files 8-K
Ticker: KTTAW · Form: 8-K · Filed: Sep 16, 2025 · CIK: 1841330
Sentiment: neutral
Topics: 8-K, corporate-filing, pharmaceuticals
TL;DR
Pasithea Therapeutics filed an 8-K on Sept 16, 2025, covering Reg FD, other events, and financials.
AI Summary
Pasithea Therapeutics Corp. filed an 8-K on September 16, 2025, reporting on events including Regulation FD disclosures, other events, and financial statements. The company, incorporated in Delaware with its principal executive offices in Miami Beach, Florida, is in the pharmaceutical preparations industry.
Why It Matters
This filing provides an update on Pasithea Therapeutics' corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status and any material events.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for corporate reporting and does not appear to contain significant new risks.
Key Numbers
- 001-40804 — SEC File Number (Identifies the company's filing with the SEC.)
- 85-1591963 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Pasithea Therapeutics Corp. (company) — Registrant
- September 16, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Miami Beach, Florida (location) — Address of principal executive offices
- 2834 (sic_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What specific events are covered under the 'Other Events' section of this 8-K filing?
The provided text does not detail the specific 'Other Events' but lists it as an item information category for the 8-K filing.
What is the primary business of Pasithea Therapeutics Corp. according to the filing?
Pasithea Therapeutics Corp. is classified under Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on September 16, 2025.
In which state was Pasithea Therapeutics Corp. incorporated?
Pasithea Therapeutics Corp. was incorporated in Delaware.
What is the address of Pasithea Therapeutics Corp.'s principal executive offices?
The principal executive offices of Pasithea Therapeutics Corp. are located at 1111 Lincoln Road, Suite 500, Miami Beach, Florida, 33139.
Filing Stats: 1,024 words · 4 min read · ~3 pages · Grade level 14.1 · Accepted 2025-09-16 07:04:47
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share KTTA The Nasdaq Capital M
Filing Documents
- ea0257501-8k_pasithea.htm (8-K) — 32KB
- ea025750101ex99-1_pasithea.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 6KB
- 0001213900-25-087903.txt ( ) — 271KB
- ktta-20250916.xsd (EX-101.SCH) — 4KB
- ktta-20250916_def.xml (EX-101.DEF) — 26KB
- ktta-20250916_lab.xml (EX-101.LAB) — 36KB
- ktta-20250916_pre.xml (EX-101.PRE) — 25KB
- ea0257501-8k_pasithea_htm.xml (XML) — 6KB
01 Regulation FD
Item 7.01 Regulation FD On September 16, 2025, Pasithea Therapeutics Corp. (the "Company") issued the Press Release (as defined below). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.
01 Other Events
Item 8.01 Other Events. On September 16, 2025, the Company issued a press release (the "Press Release") relating to its Phase 1/1b open-label study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PAS-004 in adult participants with neurofibromatosis type 1 (NF1) (the "NF1 Trial"), announcing the activation of two clinical trial sites in South Korea—Asan Medical Centre and Severance Hospital Yonsei University Health System. These sites are now actively recruiting trial participants, and the first patient in South Korea has been dosed. Beyond South Korea, the NF1 Trial is currently enrolling patients in Cohort 2, 8mg tablet, following the recent recommendation by the external Safety Review Committee to proceed past Cohort 1, 4mg tablet, without modification. Initial interim clinical data from the first two cohorts of the NF1 Trial is expected in the first quarter of 2026.
Forward Looking Statements
Forward Looking Statements This Current Report on Form 8-K contains statements that constitute "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company's ongoing Phase 1 clinical trial of PAS-004 in advanced cancer patients, the Company's ongoing Phase 1/1b clinical trial of PAS-004 in adult NF1 patients with NF1-associated plexiform neurofibromas, and the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company's current views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company's plans, assumptions, expectations, beliefs and objectives, the success of the Company's current and future business strategies, product development, pre-clinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth and financing opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this Current Report. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including risks that future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well as other factors set forth in the Company's most rece
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated September 16, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PASITHEA THERAPEUTICS CORP. Date: September 16, 2025 By: /s/ Tiago Reis Marques Name: Tiago Reis Marques Title: Chief Executive Officer 2